Expression phenotype changes of EBV-transformed lymphoblastoid cell lines during long-term subculture and its clinical significance

Cell Proliferation

Volumn 43, Issue 4, 2010, Pages 378-384

  Lee, J E ^a   Nam, H Y ^a   Shim, S M ^a   Bae, G R ^a   Han, B G ^a   Jeon, J P ^a  

^a Korea National Institute of Health   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13;

ARTICLE; CELL CULTURE; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE SEQUENCE; HUMAN; LYMPHOBLASTOID CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; QUANTITATIVE ANALYSIS; UNINDEXED SEQUENCE;

BASE SEQUENCE; CELL LINE; CELL LINE, TRANSFORMED; HERPESVIRUS 4, HUMAN; HUMANS; MICRORNAS; NF-KAPPA B; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 13; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

HUMAN HERPESVIRUS 4;

EID: 77954271334     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2010.00687.x     Document Type: Article

References (33)

1. Hu VW, Sarachana T, Kim KS, Nguyen A, Kulkarni S, Steinberg ME et al. (2009) Gene expression profiling differentiates autism case-controls and phenotypic variants of autism spectrum disorders: evidence for circadian rhythm dysfunction in severe autism. Autism Res. 2, 78 97.
2. Xie J, Techritz S, Haebel S, Horn A, Neitzel H, Klose J et al. (2005) A two-dimensional electrophoretic map of human mitochondrial proteins from immortalized lymphoblastoid cell lines: a prerequisite to study mitochondrial disorders in patients. Proteomics 5, 2981 2999.
3. Shukla SJ, Dolan ME (2005) Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics 6, 303 310.
4. Valle M, Plon SE, Rabin KR (2009) Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk. Res. 33, 336 339.
5. Brennan EP, Ehrich M, Brazil DP, Crean JK, Murphy M, Sadlier DM et al. (2009) Comparative analysis of DNA methylation profiles in peripheral blood leukocytes versus lymphoblastoid cell lines. Epigenetics 4, 159 164.
6. Jeon JP, Shim SM, Nam HY, Baik SY, Kim JW, Han BG (2007) Copy number increase of 1p36.33 and mitochondrial henome amplification in Epstein-Barr virus-transformed lymphoblastoid cell lines. Cancer Genet. Cytogenet. 173, 122 130.
7. Jeon JP, Nam HY, Shim SM, Han BG (2009) Sustained viral activity of Epstein-Barr virus contributes to cellular immortalization of lymphoblastoid cell lines. Mol. Cells 27, 143 148.
8. Kim KJ, Lee HJ, Park MH, Cha SH, Kim KS, Kim HT et al. (2006) SNP identification, linkage disequilibrium, and haplotype analysis for a 200-kb genomic region in a Korean population. Genomics 88, 535 540.
9. Yoo YK, Ke X, Hong S, Jang HY, Park K, Kim S et al. (2006) Fine-scale map of encyclopedia of DNA elements regions in the Korean population. Genetics 774, 491 497.
10. Cameron JE, Yin Q, Fewell C, Lacey M, McBride J, Wang X et al. (2008) Epstein-Barr virus latent membrane protein 1 induces cellular microRNA miR-146a, a modulator of lymphocyte signaling pathways. J. Virol. 82, 1946 1958.
11. Abaan OD, Toretsky JA (2008) PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev. 27, 205 214.
12. Kroismayr R, Baranyi U, Stehlik C, Dorfleutner A, Binder BR, Lipp J (2004) HERC5, a HECT E3 ubiquitin ligase tightly regulated in LPS activated endothelial cells. J. Cell Sci. 117, 4749 4756.
13. Forte E, Luftig MA (2009) MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J. Virol. 83, 2491 2499.
14. Faumont N, Durand-Panteix S, Schlee M, Gromminger S, Schuhmacher M, Holzel M et al. (2009) c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. J. Virol. 83, 5014 5027.
15. Sun Y, Qiao L, Xia HH, Lin MC, Zou B, Yuan Y et al. (2008) Regulation of XAF1 expression in human colon cancer cell by interferon ß: activation by the transcription regulator STAT1. Cancer Lett. 260, 62 71.
16. Pekarsky Y, Hallas C, Croce CM (2001) Molecular basis of mature T-cell leukemia. J. Am. Med. Assoc. 286, 2308 2314.
17. Teitell MA (2005) The TCL1 family of oncoproteins: co-activators of transformation. Nat. Rev. Cancer 5, 640 648.
18. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. (2001) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503 511.
19. Miyake K, Yamashita Y, Hitoshi Y, Takatsu K, Kimoto M (1994) Murine B cell proliferation and protection from apoptosis with as antibody against a 105-kd molecule: unresponsiveness of X-linked immunodeficient B cells. J. Exp. Med. 180, 1217 1224.
20. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 103, 2257 2261.
21. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A (2008) Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc. Natl. Acad. Sci. USA 105, 7269 7274.
22. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S et al. (2005) The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. USA 102, 19075 19080.
23. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C et al. (2008) Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3, e2557.
24. Lin SL, Chiang A, Chang D, Ying SY (2008) Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14, 417 424.
25. Ishihara A, Tsuda H, Kitagawa K, Yoneda M, Shiraishi T (2009) Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features. Breast Cancer 16, 179 185.
26. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198 5208.
27. Bruland O, Fluge O, Immervoll H, Balteskard L, Myklebust M, Skarstein A et al. (2008) Gene expression reveals two distinct groups of anal carcinomas with clinical implications. Br. J. Cancer 98, 1264 1273.
28. Dellas A, Jundt G, Sartorius G, Schneider M, Moch H (2009) Combined PTEN and p27kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas. Clin. Cancer Res. 15, 2456 2462.
29. Colombo J, Fachel AA, De FreitasCalmon M, Cury PM, Fukuyama EE, Tajara EH et al. (2009) Gene expression profiling reveals molecular marker candidates of laryngeal squamous cell carcinoma. Oncol. Rep. 21, 649 643.
30. Nakamura E, Iwakawa M, Furuta R, Ohno T, Satoh T, Nakawatari M et al. (2009) Villin1, a novel diagnostic marker for cervical adenocarcinoma. Cancer Biol. Ther. 8, 1146 1153.
31. Dolinkova M, Dostalova I, Lacinova Z, Michalsky D, Haluzikova D, Mraz M et al. (2008) The endocrine profile of subcutaneous and visceral adipose tissue of obese patients. Mol. Cell. Endocrinol. 291, 63 70.
32. Muurling M, van den Hoek AM, Mensink RP, Pijl H, Romijn JA, Havekes LM et al. (2004) Overexpression of APOC1 in obob mice leads to hepatic steatosis and severe hepatic insulin resistance. J. Lipid Res. 45, 9 16.
33. Jong MC, Voshol PJ, Muurling M, Dahlmans VE, Romijn JA, Pijl H et al. (2001) Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 50, 2779 2785.